This report assesses the impact of COVID-19 on lung cancer screening and diagnostics, highlighting pre-existing system weaknesses worsened by the pandemic. It documents significant delays in diagnosis, reduced screening volumes, and increased late-stage presentations. These disruptions threaten survival outcomes for a disease where early detection is critical. The report calls for rebuilding services with greater resilience, leveraging innovations in diagnostics, data, and personalized medicine. It emphasizes coordinated action across health systems, policymakers, and industry to address backlogs and ensure timely access to care.

Join for free to read